An Act relative to patient access to biomarker testing to provide appropriate therapy

HD 2335 requires health insurers and Medicaid plans in Massachusetts to cover biomarker testing for patients when the test is supported by medical evidence, such as FDA approvals, CMS guidelines, or nationally recognized clinical practice guidelines. It directly affects patients needing personalized treatment (e.g., cancer care) and insurers, mandating coverage for diagnosis, treatment, or monitoring of diseases. Key provisions include strict timelines for prior authorization decisions (72 hours standard, 24 hours in emergencies), limits on requiring multiple biopsies, and clear processes for patients to appeal coverage denials. The bill ensures access to evidence-based testing without unnecessary delays or disruptions in care.